Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma

BMC Cancer - United Kingdom
doi 10.1186/s12885-018-5116-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation

Green Medical Journal
2020English

OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

Molecular and Cellular Proteomics
BiochemistryMedicineAnalytical ChemistryMolecular Biology
2017English

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Cancer Research and Treatment
Cancer ResearchOncology
2018English

Relationship Between EGFR Mutation and Computed Tomography Characteristics of the Lung in Patients With Lung Adenocarcinoma

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy